VCNX vs. TENX, KTTA, IBIO, SHPH, BFRI, PULM, ASLN, AIMD, CVKD, and HEPA
Should you be buying Vaccinex stock or one of its competitors? The main competitors of Vaccinex include Tenax Therapeutics (TENX), Pasithea Therapeutics (KTTA), iBio (IBIO), Shuttle Pharmaceuticals (SHPH), Biofrontera (BFRI), Pulmatrix (PULM), ASLAN Pharmaceuticals (ASLN), Ainos (AIMD), Cadrenal Therapeutics (CVKD), and Hepion Pharmaceuticals (HEPA). These companies are all part of the "pharmaceutical preparations" industry.
Vaccinex (NASDAQ:VCNX) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.
Vaccinex has a beta of 0.74, indicating that its stock price is 26% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 2.25, indicating that its stock price is 125% more volatile than the S&P 500.
Tenax Therapeutics received 17 more outperform votes than Vaccinex when rated by MarketBeat users. However, 60.00% of users gave Vaccinex an outperform vote while only 58.58% of users gave Tenax Therapeutics an outperform vote.
Tenax Therapeutics has a consensus target price of $480.00, suggesting a potential upside of 13,614.29%. Given Tenax Therapeutics' higher probable upside, analysts plainly believe Tenax Therapeutics is more favorable than Vaccinex.
Tenax Therapeutics has lower revenue, but higher earnings than Vaccinex.
Tenax Therapeutics' return on equity of -65.79% beat Vaccinex's return on equity.
In the previous week, Tenax Therapeutics had 3 more articles in the media than Vaccinex. MarketBeat recorded 6 mentions for Tenax Therapeutics and 3 mentions for Vaccinex. Vaccinex's average media sentiment score of 1.12 beat Tenax Therapeutics' score of 0.33 indicating that Vaccinex is being referred to more favorably in the media.
50.1% of Vaccinex shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 51.5% of Vaccinex shares are held by insiders. Comparatively, 1.9% of Tenax Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Tenax Therapeutics beats Vaccinex on 8 of the 13 factors compared between the two stocks.
Get Vaccinex News Delivered to You Automatically
Sign up to receive the latest news and ratings for VCNX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VCNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vaccinex Competitors List
Related Companies and Tools
